Enhanced b cell cytotoxicity of cdim binding antibody
OwnerNeelima M. Bhat, Marcia M. Bieber +2inventors
InventorsNeelima M. Bhat, Marcia M. Bieber, Nelson N.H. Teng, Martin E. Sanders
Life of this patent
Estimating the term…
Abstract
Formulations and methods of treating human patients suffering from a condition characterized by lymphoid cancer, autoimmune disease or B cell hyperproliferation are disclosed, the treatment comprising administering (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a cytotoxic agent, including a chemotherapeutic agent, radioactive isotope, cytotoxic antibody, immunoconjugate, ligand conjugate, immunosuppressant, cell growth regulator and/or inhibitor, toxin, or mixtures thereof, including agents that disrupt the cytoskeleton of B cells, particularly vinca alkaloids or colchicine.
Claims20
A method of treating a human patient suffering from a condition characterized by a hyperproliferation of B cells, comprising contacting said B cells with (1) a cytotoxic amount of an antibody having specific binding for CDIM epitopes on a B cell, and (2) a chemotherapeutic agent,
- wherein said CDIM epitope is a linear lactosamine determinant on B cells sensitive to the enzyme endo-beta-galactosidase, and
- wherein the chemotherapeutic agent is administered before the antibody having specific binding for CDIM epitopes on a B cell, and
- wherein said contacting is performed by intravenous administration to the patient.
A method of augmenting the B cell cytotoxicity of an antibody that binds a CDIM epitope, comprising contacting B cells with the antibody that binds a CDIM epitope and an agent that disrupts the cytoskeleton of B cells, wherein said augmenting is used in the therapy of lymphoid cancer, B cell hyperproliferative diseases, or autoimmune diseases,
- wherein said CDIM epitope is a linear lactosamine determinant on B cells sensitive to the enzyme endo-beta-galactosidase, and
- wherein said B cells are contacted with the agent before the B cells are contacted with the antibody binding a CDIM epitope, and
- wherein said contacting is performed by parenteral injection to the patient.
A method of killing malignant B cells that are resistant to chemotherapeutic agents, cell growth regulators and/or inhibitors, or cytotoxic antibodies, comprising contacting said malignant B cells with an antibody having specific binding for CDIM epitopes on a B cell, wherein said CDIM epitope is a linear lactosamine determinant on B cells sensitive to the enzyme endo-beta-galactosidase.
Dependencies are inferred from the claim text.